Suomen Terveystalo Oy
- Address
- lock Available on a paid plan
Psychiatry and Psychology and Mental Disorders
At Suomen Terveystalo Oy in Helsinki, clinical trials in mental health focus on major depressive disorder, generalized anxiety disorder, and related symptoms such as anhedonia. The studies are designed to test new treatment options and assess whether they can improve mood, anxiety, and daily functioning in people who have not responded well to current care.
- Research on adjunctive and stand-alone approaches for major depressive disorder
- Studies targeting generalized anxiety disorder and persistent anxiety symptoms
- Trials evaluating whether new therapies can improve depressive symptoms and overall well-being
These trials reflect a strong interest in finding better options for common and often hard-to-treat psychiatric conditions.
Nervous System Diseases
The site also conducts research in neurology, with studies involving migraine, narcolepsy, and mild to moderate Alzheimer’s disease. The main goals include preventing migraine attacks, reducing daytime sleepiness, and improving thinking skills and global function in people with cognitive decline.
- Trials for migraine prevention and acute relief in adults and children
- Studies in narcolepsy and narcolepsy with cataplexy aimed at managing excessive sleepiness
- Research in Alzheimer’s disease focused on cognition and daily functioning
These investigations support the development of more effective therapies for neurological disorders that can significantly affect quality of life.
Cardiovascular Diseases
Clinical trial activity in cardiovascular diseases includes work on heart failure, hypertension, and broader cardiovascular disease risk in people with metabolic conditions. The research is aimed at improving outcomes, lowering the risk of serious heart events, and testing new treatment combinations for patients with complex disease profiles.
- Studies in heart failure with preserved or mildly reduced ejection fraction and obesity
- Trials in type 2 diabetes, hypertension, and established cardiovascular disease
- Research evaluating whether new therapies can reduce hospitalizations and cardiovascular deaths
These trials highlight a focus on better long-term care for patients with overlapping heart and metabolic conditions.
Respiratory Tract Diseases
In the area of respiratory tract diseases, the site is involved in studies on chronic obstructive pulmonary disease and related cardiopulmonary outcomes. The purpose of this research is to determine whether new treatment combinations can improve breathing-related health and reduce serious complications.
- Trials in COPD examining symptom control and overall respiratory outcomes
- Research linking lung disease treatment with broader cardiopulmonary benefits
- Studies designed to evaluate the effectiveness of new inhaled and combined therapies
This work supports efforts to improve both daily respiratory symptoms and longer-term disease control.
Digestive System Diseases
Research in digestive system diseases centers on celiac disease, with trials exploring ways to reduce gluten-related intestinal injury and improve disease management. The main objective is to test new therapies that may protect the gut and offer better control of symptoms and inflammation.
- Studies in celiac disease focused on reducing gluten-induced intestinal damage
- Research aimed at improving treatment options for people living with ongoing dietary sensitivity
- Clinical testing of approaches intended to support safer and more effective disease control
This area adds an important digestive health dimension to the broader clinical research portfolio at the site.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Suomen Terveystalo Oy
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Aticaprant as Adjunctive Therapy in Adults with Major Depressive Disorder and Anhedonia Unresponsive to Antidepressants | Janssen Cilag International | Phase III | Not Recruiting | Nov 2024 | Feb 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aticaprant | 1 | Unknown | 2024-11-14 | 2024-11-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
